Patents by Inventor Mong-Heng Wang

Mong-Heng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11135187
    Abstract: Compositions and methods for treating diabetic retinopathy or symptoms thereof are provided. The disclosed compositions and methods for treating diabetic retinopathy contravene the existing paradigm that Renin-Angiotensin System (RAS) blockade alone can treat, prevent, or reduce diabetic retinopathy. The disclosed compositions and methods include a combination or alternation of EET antagonists and ATI antagonists.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 5, 2021
    Assignees: National Institutes of Health (NIH), U.S. Dept. of Health Human Services, (DHHS), U.S. Government NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Mong Heng Wang, Mohamed Al-Shabrawey
  • Publication number: 20190060259
    Abstract: Compositions and methods for treating diabetic retinopathy or symptoms thereof are provided. The disclosed compositions and methods for treating diabetic retinopathy contravene the existing paradigm that Renin-Angiotensin System (RAS) blockade alone can treat, prevent, or reduce diabetic retinopathy. The disclosed compositions and methods include a combination or alternation of EET antagonists and ATI antagonists.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Mong Heng Wang, Mohamed Al-Shabrawey
  • Patent number: 9480664
    Abstract: Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET0016. The compositions have reduced side effects due to COX inhibitors. Methods for treating or inhibiting cancer using the disclosed compositions are also provided.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Mong-Heng Wang
  • Publication number: 20160022614
    Abstract: Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET0016. The compositions have reduced side effects due to COX inhibitors. Methods for treating or inhibiting cancer using the disclosed compositions are also provided.
    Type: Application
    Filed: July 27, 2015
    Publication date: January 28, 2016
    Inventor: Mong-Heng Wang